Healthcare & Medical Devices Global On demand · 24-48h

Global Safety IV Catheter Market Strategic Research Report

Global Safety IV Catheter Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Safety IV Catheter Market
$2.47B2025
5.4%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: No Blood Control, Single Blood Control, Multiple Blood Control

By Application: Intravenous Infusion, Blood Sampling, Blood Pressure Monitoring, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: B. Braun SE, ICU Medical, Inc., Becton, Dickinson and Company, JCM MED, Poly Medicure Limited, MedSource Labs, Terumo Corporation, Greiner Bio-One International GmbH, MEDIKIT Co., Ltd., Nipro Corporation, Vygon SA, Zhejiang Kindly Medical Devices Co., Ltd., Suzhou Linhwa Medical Devices Co., Ltd., PW Medtech Group Limited, Delta Med S.p.A., Angiplast Pvt. Ltd., Harsoria Healthcare Pvt. Ltd., Woo Young Medical Co., Ltd., Young Corporation, Forlong Medical Co., Ltd., Kohope Medical Co., Ltd., USM Healthcare Medical Devices Factory JSC, SBRG Medtech Pvt. Ltd.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 154 pages
Market size 2025
$2.47B
Billion USD
Forecast CAGR
5.4%
2025-2032
Forecast 2032
$3.6B
Projected
Régions
5
Asia Pacific · Latin America · MEA · Europe · North America

Vue d'ensemble

Scope of the Report

The global Safety IV Catheter market size is predicted to grow from US$ 2,472 million in 2025 to US$ 3,657 million in 2032; it is expected to grow at a CAGR of 5.4% from 2026 to 2032.

Safety IV catheters are sterile, single-use intravascular catheter products designed for short-term peripheral vascular access. Their core function is to establish stable vascular access for patients during infusion, drug administration, blood sampling, blood pressure monitoring, and selected power-injection contrast imaging procedures, while reducing nursing risks such as needlestick injuries, exposure to bloodborne pathogens, blood leakage contamination, and repeated punctures through structures including needle-tip shielding, inner-needle retraction, metallic clip protection, full-encapsulation sleeves, hemostatic valves, blood-control valves, and closed connection systems. These products typically consist of a metal introducer needle, peripheral catheter, catheter hub, flashback chamber, protective housing, needle-tip protection mechanism, injection port, extension tube, valve components, and sterile packaging. Catheter materials include polyurethane, polytetrafluoroethylene, fluorinated ethylene propylene, and thermosensitive polyurethane. Common sizes generally range from 14G to 26G, with different models developed for adult, pediatric, neonatal, routine infusion, blood-control, and power-injectable use scenarios. Typical customers include general hospitals, emergency centers, operating rooms, ICUs, pediatric departments, imaging departments, outpatient infusion centers, distributors, and OEM medical consumable brands.

The industrial value of safety IV catheters is shifting from a single venipuncture consumable to a standardized medical device that combines vascular access, safety protection, and nursing workflow management. Peripheral venous access is one of the most common basic procedures in clinical care. Conventional IV catheters mainly address continuous infusion and reduce repeated punctures, but occupational exposure risks remain during needle withdrawal, catheter connection, blood leakage, and sharps disposal. As hospitals place greater emphasis on infection control, occupational protection, and nursing quality, safety-engineered products are becoming an increasingly important procurement direction. The essence of product upgrading is not simply adding a protective shell, but building a complete risk-control system around the cannulation process, including flashback visualization, automated needle-tip protection, blood-control valves, closed connections, catheter flexibility, radiopacity, and size selection. For hospitals, these products can reduce needlestick injuries, limit blood contamination, improve procedural consistency, and enhance safety in high-frequency settings such as emergency departments, ICUs, operating rooms, pediatric units, and imaging departments. Therefore, market growth is driven more by clinical standard upgrades and replacement within hospital consumable portfolios than by patient volume alone.

The competitive landscape is characterized by the coexistence of technology-driven product portfolios from international leaders and cost-efficient manufacturing from regional suppliers. Companies in Europe, the United States, and Japan generally build barriers around safety mechanisms, material systems, clinical training, and regulatory certification, with portfolios covering active retraction, passive protection, blood control, closed systems, power-injectable models, and pediatric or neonatal sizes. Manufacturers in India, China, South Korea, and Vietnam are competitive in production cost, size coverage, OEM supply, and regional channels, and some have launched products with blood control, power-injection capability, needlestick protection, and closed-system structures. Safety mechanism is the key factor in competitive segmentation. Passive clips and full-encapsulation sleeves emphasize automation and lower training burden, active push-button or slide retraction emphasizes operational control, and blood-control or multi-access valves further enhance infection-control value. Since these products contact the vascular system directly and involve sterility, material compatibility, and sharps protection, market entry requires medical device registration, sterilization validation, material safety, needle-tip protection reliability, and batch consistency. Future competition will move from individual low-price products toward integrated solutions centered on clinical scenarios, nursing workflows, and full-size portfolios.

Future growth will concentrate on blood control, closed systems, power-injectable imaging applications, pediatric and neonatal sizes, and regional localization. Blood-control products can reduce leakage during cannulation and connection, making them suitable for emergency departments, ICUs, infection-control settings, and high-turnover wards. Closed systems reduce open connections and manual venous compression, helping improve nursing safety and workflow efficiency. Power-injectable safety IV catheters can be linked to CT contrast imaging and raise the application value of a single catheter. Pediatric and neonatal products require smaller gauges, lower trauma, stable flashback, and stronger contamination control. From a policy perspective, occupational exposure protection, bloodborne pathogen risk control, and registration review requirements for sterile single-use devices will continue to support product standardization. In terms of consumption regions, North America, Europe, and Japan tend to favor high-safety configurations and branded products, while China is shaped by tender procurement, domestic substitution, and upgraded hospital safety management. India and Southeast Asia combine local manufacturing with export potential. Overall, safety IV catheters remain a structural upgrade category within basic medical consumables, with long-term replacement space and steady growth characteristics.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Safety IV Catheter market?

What factors are driving Safety IV Catheter market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Safety IV Catheter market opportunities vary by end market size?

How does Safety IV Catheter break out by Blood Control, by Application?

This report presents a comprehensive overview of the global Safety IV Catheter market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Blood Control

  • No Blood Control
  • Single Blood Control
  • Multiple Blood Control

Segment by Structural Configuration

  • Wingless Straight
  • Winged

Segment by Safety Mechanism

  • Active Retraction
  • Passive Clip
  • Other

Segment by Application

  • Intravenous Infusion
  • Blood Sampling
  • Blood Pressure Monitoring
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Safety IV Catheter market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Intravenous Infusion, Blood Sampling, Blood Pressure Monitoring evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Safety IV Catheter Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 5.4%
Regional growth momentum
Market share by segment
Key metrics
Base value
$2.47B
2025
Forecast
$3.6B
2032
CAGR
5.4%
2025–2032
Régions
5
global
Key companies
B. Braun SEICU Medical, Inc.BectonDickinson and CompanyJCM MEDPoly Medicure LimitedMedSource LabsTerumo Corporation
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
No Blood ControlSingle Blood ControlMultiple Blood Control
By Application
Intravenous InfusionBlood SamplingBlood Pressure MonitoringOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 No Blood Control
  • 3.1.3 Single Blood Control
  • 3.1.4 Multiple Blood Control
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Intravenous Infusion
  • 4.1.3 Blood Sampling
  • 4.1.4 Blood Pressure Monitoring
  • 4.1.5 Other
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 B. Braun SE
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 ICU Medical, Inc.
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Becton, Dickinson and Company
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 JCM MED
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Poly Medicure Limited
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 MedSource Labs
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Terumo Corporation
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Greiner Bio-One International GmbH
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 MEDIKIT Co., Ltd.
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Nipro Corporation
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Vygon SA
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Zhejiang Kindly Medical Devices Co., Ltd.
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Suzhou Linhwa Medical Devices Co., Ltd.
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 PW Medtech Group Limited
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Delta Med S.p.A.
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Angiplast Pvt. Ltd.
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Harsoria Healthcare Pvt. Ltd.
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Woo Young Medical Co., Ltd.
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Young Corporation
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Forlong Medical Co., Ltd.
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Kohope Medical Co., Ltd.
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 USM Healthcare Medical Devices Factory JSC
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 SBRG Medtech Pvt. Ltd.
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Safety IV Catheter market?
The global Safety IV Catheter market is estimated at US$ 2.47 billion in 2025 (base year) and is projected to reach US$ 3.66 billion by 2032.
How fast is the Safety IV Catheter market expected to grow?
The market is expected to grow at a CAGR of 5.4% from 2026 to 2032, expanding from US$ 2.47 billion in 2025 to US$ 3.66 billion in 2032, roughly 1.5 times its base-year value.
What does the Safety IV Catheter market cover?
Safety IV catheters are sterile, single-use intravascular catheter products designed for short-term peripheral vascular access. These products typically consist of a metal introducer needle, peripheral catheter, catheter hub, flashback chamber, protective housing, needle-tip protection mechanism, injection port, extension tube, valve components, and sterile packaging.
What are the main segments of the Safety IV Catheter market by blood control?
By blood control, the market is segmented into No Blood Control, Single Blood Control and Multiple Blood Control.
Which applications drive demand in the Safety IV Catheter market?
Key applications covered include Intravenous Infusion, Blood Sampling, Blood Pressure Monitoring and Other.
Who are the key players in the Safety IV Catheter market?
Key players profiled include B. Braun SE, ICU Medical, Becton, Dickinson and Company, JCM MED, Poly Medicure Limited, MedSource Labs, Terumo Corporation and Greiner Bio-One International GmbH, among 23 companies covered in total.
Which regions and countries are covered for Safety IV Catheter?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What is driving growth in the Safety IV Catheter market?
Therefore, market growth is driven more by clinical standard upgrades and replacement within hospital consumable portfolios than by patient volume alone.
What challenges does the Safety IV Catheter market face?
Companies in Europe, the United States, and Japan generally build barriers around safety mechanisms, material systems, clinical training, and regulatory certification, with portfolios covering active retraction, passive protection, blood control, closed systems, power-injectable models, and pediatric or neonatal sizes.
Who should buy the Safety IV Catheter market report?
The report is intended for manufacturers and solution providers, distributors and end users in Intravenous Infusion, Blood Sampling and Blood Pressure Monitoring, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Safety IV Catheter market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3 500,00 $US
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.